TY - JOUR
T1 - Incretin-based therapy for glycemic control of hospitalized patients with type 2 diabetes
T2 - a systematic review
AU - Gracia-Ramos, A. E.
AU - Cruz-Domínguez, M. P.
AU - Madrigal-Santillán, E. O.
N1 - Publisher Copyright:
© 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)
PY - 2022/3
Y1 - 2022/3
N2 - Incretin-based therapy leads to glycemic control in a glucose-dependent manner with a low risk of hypoglycemia, making it appealing for use in the hospital. The aim of this systematic review was to assess the benefits of incretin-based therapy in patients with type 2 diabetes hospitalized outside of the intensive care unit. We searched for studies published up to August 2021 in the PubMed and Scopus databases. Clinical trials comparing incretin-based therapy (alone or in combination with insulin) versus an insulin regimen were selected. The results of the included studies showed that incretin-based therapy showed mean blood glucose values, a percentage of records within the therapeutic target, and a percentage of treatment failure similar to insulin management, particularly in patients with mild to moderate hyperglycemia. Furthermore, incretin-based treatment was associated with a lower total insulin dose and a lower incidence of hypoglycemia. In conclusion, incretin-based therapy achieved glycemic control similar to insulin treatment in patients with type 2 diabetes hospitalized outside the intensive care unit and has the advantages of reducing the insulin requirement and a lower risk of hypoglycemia.
AB - Incretin-based therapy leads to glycemic control in a glucose-dependent manner with a low risk of hypoglycemia, making it appealing for use in the hospital. The aim of this systematic review was to assess the benefits of incretin-based therapy in patients with type 2 diabetes hospitalized outside of the intensive care unit. We searched for studies published up to August 2021 in the PubMed and Scopus databases. Clinical trials comparing incretin-based therapy (alone or in combination with insulin) versus an insulin regimen were selected. The results of the included studies showed that incretin-based therapy showed mean blood glucose values, a percentage of records within the therapeutic target, and a percentage of treatment failure similar to insulin management, particularly in patients with mild to moderate hyperglycemia. Furthermore, incretin-based treatment was associated with a lower total insulin dose and a lower incidence of hypoglycemia. In conclusion, incretin-based therapy achieved glycemic control similar to insulin treatment in patients with type 2 diabetes hospitalized outside the intensive care unit and has the advantages of reducing the insulin requirement and a lower risk of hypoglycemia.
KW - Antidiabetics
KW - Diabetes
KW - Incretins
KW - Inpatient
KW - Insulin
UR - http://www.scopus.com/inward/record.url?scp=85118359377&partnerID=8YFLogxK
U2 - 10.1016/j.rce.2021.09.002
DO - 10.1016/j.rce.2021.09.002
M3 - Artículo de revisión
AN - SCOPUS:85118359377
SN - 0014-2565
VL - 222
SP - 180
EP - 189
JO - Revista Clinica Espanola
JF - Revista Clinica Espanola
IS - 3
ER -